ABSTRACT
Human carbonic anhydrase IX (CA IX), a protein specifically expressed on the surface of solid tumour cells, represents a validated target both for anticancer therapy and diagnostics. We recently identified sulfonamide dicarbaboranes as promising inhibitors of CA IX with favourable activities both in vitro and in vivo. To explain their selectivity and potency, we performed detailed X-ray structural analysis of their interactions within the active sites of CA IX and CA II. Series of compounds bearing various aliphatic linkers between the dicarbaborane cluster and sulfonamide group were examined. Preferential binding towards the hydrophobic part of the active site cavity was observed. Selectivity towards CA IX lies in the shape complementarity of the dicarbaborane cluster with a specific CA IX hydrophobic patch containing V131 residue. The bulky side chain of F131 residue in CA II alters the shape of the catalytic cavity, disrupting favourable interactions of the spherical dicarbaborane cluster.
Subject(s)
Antineoplastic Agents/chemistry , Boron Compounds/chemistry , Carbonic Anhydrase IX/antagonists & inhibitors , Carbonic Anhydrase Inhibitors/chemistry , Sulfonamides/chemistry , Amino Acid Sequence , Antigens, Neoplasm/genetics , Antineoplastic Agents/pharmacology , Carbonic Anhydrase IX/genetics , Carbonic Anhydrase Inhibitors/pharmacology , Catalytic Domain , Crystallography, X-Ray , Drug Screening Assays, Antitumor , HEK293 Cells , Humans , Hydrophobic and Hydrophilic Interactions , Protein Binding , Structure-Activity Relationship , Sulfonamides/pharmacologyABSTRACT
Carbonic anhydrase IX (CA IX) is a transmembrane enzyme overexpressed in hypoxic tumors, where it plays an important role in tumor progression. Specific CA IX inhibitors potentially could serve as anti-cancer drugs. We designed a series of sulfonamide inhibitors containing carborane clusters based on prior structural knowledge of carborane binding into the enzyme active site. Two types of carborane clusters, 12-vertex dicarba-closo-dodecaborane and 11-vertex 7,8-dicarba-nido-undecaborate (dicarbollide), were connected to a sulfonamide moiety via aliphatic linkers of varying lengths (1-4 carbon atoms; n = 1-4). In vitro testing of CA inhibitory potencies revealed that the optimal linker length for selective inhibition of CA IX was n = 3. A 1-sulfamidopropyl-1,2-dicarba-closo-dodecaborane (3) emerged as the strongest CA IX inhibitor from this series, with a Ki value of 0.5 nM and roughly 1230-fold selectivity towards CA IX over CA II. X-ray studies of 3 yielded structural insights into their binding modes within the CA IX active site. Compound 3 exhibited moderate cytotoxicity against cancer cell lines and primary cell lines in 2D cultures. Cytotoxicity towards multicellular spheroids was also observed. Moreover, 3 significantly lowered the amount of CA IX on the cell surface both in 2D cultures and spheroids and facilitated penetration of doxorubicin. Although 3 had only a moderate effect on tumor size in mice, we observed favorable ADME properties and pharmacokinetics in mice, and preferential presence in brain over serum.
Subject(s)
Antineoplastic Agents/pharmacology , Breast Neoplasms/drug therapy , Carbonic Anhydrase IX/antagonists & inhibitors , Carbonic Anhydrase Inhibitors/pharmacology , Sulfonamides/pharmacology , Animals , Antigens, Neoplasm/metabolism , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Breast Neoplasms/metabolism , Carbonic Anhydrase IX/metabolism , Carbonic Anhydrase Inhibitors/chemical synthesis , Carbonic Anhydrase Inhibitors/chemistry , Cell Proliferation/drug effects , Cells, Cultured , Dogs , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Humans , Mice , Mice, Inbred BALB C , Mice, SCID , Molecular Structure , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/metabolism , Recombinant Proteins/metabolism , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/chemistryABSTRACT
Although 1-Ph-2-X-closo-1,2-C2B10H10 (X = F, Cl, Br, I) derivatives had been computed to have positive values of the heat of formation, it was possible to prepare them. The corresponding solid-state structures were computationally analyzed. Electrostatic potential computations indicated the presence of highly positive σ-holes in the case of heavy halogens. Surprisingly, the halogenâ¢â¢â¢π interaction formed by the Br atom was found to be more favorable than that of I.
Subject(s)
Boron Compounds/chemistry , Carbon/chemistry , Halogens/chemistry , Boron Compounds/chemical synthesis , Chemistry Techniques, Synthetic , Halogenation , Models, Molecular , Molecular ConformationABSTRACT
The world's population is now over 50% urban, and cities make an important contribution to national greenhouse gas (GHG) emissions. Many cities are developing strategies to reduce their emissions. Here we ask how and why emissions differ between cities. Our study often global cities shows how a balance of geophysical factors (climate, access to resources, and gateway status) and technical factors (power generation, urban design, and waste processing) determine the GHGs attributable to cities. Within the overall trends, however, there are differences between cities with more or less public transit while personal income also impacts heating and industrial fuel use. By including upstream emissions from fuels, GHG emissions attributable to cities exceed those from direct end use by upto 25%. Our findings should help foster intercity learning on reducing GHG emissions.
Subject(s)
Air Pollutants/chemistry , Cities , Greenhouse Effect , Atmosphere , Canada , Czech Republic , London , South Africa , Spain , Switzerland , Thailand , United StatesABSTRACT
Structure based ligand design was used in order to design a partial agonist for the PPARdelta receptor. The maximum activation in the transactivation assay was reduced from 87% to 39%. The crystal structure of the ligand binding domain of the PPARdelta receptor in complex with compound 2 was determined in order to understand the structural changes which gave rise to the decrease in maximum activation.
Subject(s)
Butyrates/chemistry , Butyrates/pharmacology , PPAR delta/agonists , Phenylurea Compounds/chemistry , Phenylurea Compounds/pharmacology , Thiazoles/chemistry , Thiazoles/pharmacology , Drug Design , Models, Molecular , Molecular Structure , Structure-Activity RelationshipABSTRACT
Y-shaped molecules bearing alkynylallylic moieties were found to be potent and selective PPARdelta activators. The alkynylallylic moiety was synthesized from alkyn-1-ols by hydroalumination followed by a cross-coupling reaction. Series of active compounds 6 were obtained by stepwise changing the structure of the known PPARpan agonist 5 into Y-shaped compounds. The most active and selective compound, 6f, had a PPARdelta potency of 0.13 microM, which is 50-fold more potent than compound 5.
Subject(s)
PPAR delta/agonists , Models, Molecular , Molecular StructureABSTRACT
Computational analysis of the ligand binding pocket of the three PPAR receptor subtypes was utilized in the design of potent PPARalpha agonists. Optimum PPARalpha potency and selectivity were obtained with substituents having van der Waals volume around 260. Compound 6 had a PPARalpha potency of 0.002 microM and a selectivity ratio to PPARgamma and PPARdelta of 410 and 2000, respectively.
Subject(s)
Drug Design , PPAR alpha/agonists , Phenylpropionates/chemistry , Phenylpropionates/pharmacology , Animals , Computers , Crystallography , Ligands , PPAR alpha/chemistry , Phenylpropionates/chemical synthesisABSTRACT
The aim was to identify a novel selective PPARdelta agonist with full efficacy on free fatty acid (FFA) oxidation in vitro and plasma lipid correction in vivo. Using the triple PPARalpha,gamma,delta agonist 1 as the structural starting point, we wanted to investigate the possibility of obtaining selective PPARdelta agonists by modifying only the acidic part of 1, while holding the lipophilic half of the molecule constant. The structure-activity relationship was guided by in vitro transactivation data using the human PPAR receptors, FFA oxidation efficacy performed in the rat muscle L6 cell line, and in vivo rat pharmacokinetic properties. Compound 7 ([4-[3,3-bis-(4-bromo-phenyl)-allylthio]-2-chloro-phenoxy]-acetic acid) was identified as a selective, partial agonist with good oral pharmacokinetic properties in rat. Chronic treatment of high fat fed ApoB100/CETP-Tgn mice with 7 corrected the plasma lipid parameters and improved insulin sensitivity. These data suggest that selective PPARdelta agonists have the potential to become a novel treatment of dyslipidemia.
Subject(s)
Allyl Compounds/chemical synthesis , Lipid Metabolism/drug effects , PPAR delta/agonists , Phenylacetates/chemical synthesis , Administration, Oral , Allyl Compounds/pharmacokinetics , Allyl Compounds/pharmacology , Animals , Apolipoprotein B-100/genetics , Binding Sites , Cell Line , Cholesterol Ester Transfer Proteins/genetics , Crystallography, X-Ray , Dietary Fats/administration & dosage , Fatty Acids, Nonesterified/metabolism , Female , Humans , Male , Mice , Mice, Transgenic , Models, Molecular , Muscle, Skeletal/cytology , Oxidation-Reduction , Phenylacetates/pharmacokinetics , Phenylacetates/pharmacology , Rats , Structure-Activity Relationship , Transcriptional ActivationABSTRACT
3,3-Disubstituted prop-2-en-1-ols 4 were synthesized with a high degree of stereoselectivity from 3-substituted prop-2-yn-1-ols 1 via hydroalumination and subsequent Pd-catalyzed coupling with aryl iodides 3.